Investor FAQs

Where is Covalon Technologies Ltd.'s corporate headquarters?
1660 Tech Avenue, Unit 5, Mississauga, Ontario, Canada, L4W 5S7.
Where is the company incorporated?
Covalon Technologies Ltd. is incorporated in Canada.
When did Covalon Technologies Ltd. go public?
Covalon Technologies Ltd. was founded in 1999 and subsequently went public in 2004.
What is Covalon Technologies Ltd.’s fiscal year?
September 30
How is Covalon Technologies Ltd. stock traded?
Covalon Technologies Ltd. is traded on the TSX Venture (symbol: COV) and OTC (symbol: CVALF).
Does Covalon Technologies Ltd. pay dividends?
At this time, the company does not pay a dividend.
Who is Covalon Technologies Ltd.'s transfer agent?
TMX
Whom do I contact with questions about my stock?
Brian Pedlar bpedlar@covalon.com or Danny Brannagan dbrannagan@covalon.com.
Does Covalon Technologies Ltd. have a direct stock purchase plan?
No
Who is Covalon Technologies Ltd.'s auditor?
BDO Dunwoody LLP
What does Covalon do?
Covalon Technologies Ltd. is a researcher, developer, manufacturer, and marketer of patent-protected medical products that improve patient outcomes and save lives in the areas of advanced wound care, infection management and surgical procedures.
What is Covalon’s business model?
Covalon leverages its patented medical technology platforms and expertise in two ways: (i) we develop products that we sell under Covalon’s name; and (ii) we develop and commercialize medical products for other medical companies under development and license contracts.
How does Covalon generate revenue?
The majority of Covalon-branded products are sold through independent distributors to various health care providers such as hospitals, wound care centers, burn centers, extended/alternate care facilities, acute care facilities, home health care agencies, and physicians’ offices. Many of our products require regulatory clearances and are sold on a prescription basis in the United States, Canada, the Middle East, Latin America, Asia and a number of international countries.

We also license our technologies and products to large medical device companies as well as work with niche start-ups to create novel technology to advance their product offerings in various medical device markets. Covalon has worked with over twenty medical companies including leaders in vascular access devices, I.V. infusion, orthopedics, device and patient care distributors, wound care product companies, specialty medical device manufacturers and major contract manufacturers.
Does Covalon own any intellectual property?
Covalon currently has three proprietary platform technologies that have the potential to be developed into dozens of medical devices: (i) Biological matrix; (ii) Antimicrobial silicone adhesive; and (iii) Medical Coating technology. These platform technologies are protected by patents, patent applications and patents pending, patented and proprietary manufacturing processes, trade secrets, brands, trademarks, and trade names.
What is Covalon’s Biological Matrix technology?
The Company’s patented biological matrix platform is used to manufacture a family of products that treat chronic and infected wounds including diabetic ulcers (including diabetic foot ulcers), pressure ulcers, venous ulcers (including venous leg ulcers), donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns. These dressings begin from a biological collagen base, which is generally biocompatible with the human body, and enable the release of beneficial materials, such as antimicrobials, into the wound site and/or enhance the removal of undesirable materials, such as wound exudate from the wound. Covalon’s patented manufacturing process for creating our biological matrix results in products that have certain clinical advantages over other dressings, such as open binding sites for destructive enzymes, effective antimicrobial activity, and exudate management properties that help chronic wounds heal.
What is Covalon’s Antimicrobial Silicone Adhesive technology?
Covalon’s patent-pending antimicrobial silicone adhesive platform is the basis for a family of pre-surgical, post surgical and vascular access products that are designed to kill 99.99% or more of any bacteria or yeast that comes into contact with the antimicrobial silicone. The Company’s Antimicrobial Silicone Adhesive platform is unique because the silicone adhesive contains both silver and chlorhexidine which provides broad-spectrum antimicrobial activity for a minimum of 7 days, while maintaining the beneficial properties of a silicone adhesive. Our technology meets or exceeds the current United States Food and Drug Administration’s “greater than 4 log reduction” standard for an antimicrobial claim against bacteria, and yeast, most commonly associated with healthcare acquired infections. The soft silicone adhesive also provides greater patient comfort, does not macerate or damage the skin, and was shown to be up to 10 times less painful upon removal when compared to acrylic adhesives, which are commonly used in medical products containing adhesives.
What is Covalon’s Medical Coating technology?
Covalon’s patented Medical Coating technology, called CovaCoat is a proprietary “grafting from” process which utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. The CovaCoat process enables these grafting sites to slightly penetrate the surface of the medical device forming a strong, permanent continuum, rather than a discreet coating layer, which is more susceptible to delamination and particulate generation as compared to the resulting CovaCoat surface. This is unlike many competitors’ coatings, which use a cure catalyst. As a result, the CovaCoat process creates a functionalizable micron level covalently bound polymeric surface while preserving the bulk mechanical properties of the underlying medical device. The Company’s CovaCoat process will not decrease or adversely affect the physical properties of the underlying device, which is critical for regulatory submissions and clinical use. The new coated surface created during the CovaCoat process has inherent lubricious and biocompatible properties and can be further functionalized to meet the specific needs of an application. CovaCoat has been proven effective on many polymeric medical device surfaces including silicones, polyurethanes, polyethylenes, polycarbonates, polyesters, Pebax®, Nylon and PEEK.
Where can I find out more about Covalon Technologies Ltd.?
You can learn more about Covalon Technologies Ltd. By visiting our website www.covalon.com
Where can I get the latest corporate news releases and financial reports?
Please visit the “email alerts” page in the investor relations section of our corporate website and fill out our web form to be added to our distribution list.
How can I view Covalon Technologies Ltd.’s financial results?
Quarterly and annual reports and other investor material, when available, can be found in “Quarterly Results” in the “Financial Info” of the “Investor Relations” section of our corporate website. Additionally, all filings can be accessed directly from the website www.sedar.com.
Who makes up the Covalon Technologies Ltd. Executive Management team and Board of Directors?
You can view our management team by visiting the “Executive Management Team” section of our corporate website.
How can I obtain further information or materials on the innovative products available through Covalon Technologies Ltd.?
For more information about our products please visit the “Products” section of our corporate website.
Is there a way to receive instant updates regarding the date and times of these events?
Please visit the “email alerts” page in the investor relations section of our corporate website and fill out our web form to be added to our distribution list.
When is your next earnings release scheduled? How can I receive email updates for this information?
Covalon Technologies Ltd., reports financial results on a quarterly basis. For more information about financial releases and upcoming events please visit the “News and Events” page of “Investor Relations” section of our corporate website.
Whom should I contact regarding investor inquiries?
Brian Pedlar bpedlar@covalon.com or Danny Brannagan dbrannagan@covalon.com.
How can I obtain a copy of your annual report and proxy?
A copy of the annual report and proxy are mailed out to shareholders of record on a yearly basis. The prior year’s annual report and proxy can be found in “Quarterly Results” in the “Financial Info” of the “Investor Relations” section of our corporate website. Additionally, all filings can be accessed directly from the website www.sedar.com.